| CAS | 38101-59-6 |
| Sequence | H-Glu-Trp-OH |
| Sequence Single | EW |
| Molecular Formula | C16H19N3O5 |
| Molecular Weight | 333.35 |
| Synonyms | Thymogen, Oglufanide, IM862 |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Di- and Tripeptides|Immunomodulating Agents |
| Description | H-Glu-Trp-OH also called Thymogen, Oglufanide, IM862, is a dipeptide immunomodulator isolated from calf thymus. Oglufanide inhibits vascular endothelial growth factor (VEGF). Oglufanide can stimulate the immune response to hepatitic C virus (HCV) and intracellular bacterial infections. Oglufanide shows antitumor and anti-angiogenesis activities. Oglufanide is a substrate for aminopeptidase W, Km 0.49 mM and kcat 5557 min-1 . |
| References | 1. Dipeptidyl-aminopeptidases and aminopeptidases in Dictyostelium discoideum. S.A.T.Chan et al., Biochem. Biophys. Res. Commun., 127, 962 (1985) 2. Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. D.L.Smith et al., Int. J. Cancer, 106, 528 (2003) 3. Proteins of the kidney microvillar membrane. Enzymic and molecular properties of aminopeptidase. W. N.S.Gee and A.J.Kenny, Biochem. J., 246, 97 (1987) 4. The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice. V.I.Deigin et al., Int. Immunopharmacol., 7, 375 (2007) 5. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. Bayes M, et al. 2005 Jul-Aug;27(6):411-61. 6. Biomedical importance of indoles. Nagendra Kumar Kaushik, et al. Molecules. 2013 Jun 6;18(6):6620-62. 7. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi’s sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. Noy A, et al. J Cl 8. Natural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan. Smith DL, et al. Int J Cancer. 2003 Sep 10;106(4):528-533. |